Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Takeshi Hatanaka; Satoru Kakizaki; Noritomo Shimada; Kazuhito Kawata; Atsushi Naganuma; Hisashi Kosaka; Tomomitsu Matono; Hidekatsu Kuroda; Yutaka Yata; Hironori Tanaka; Hiroki Nishikawa; Hiroshi Shibata; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Takashi Kumada

doi:10.1038/s41598-024-78539-4

Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Hideko Ohama, Atsushi Hiraoka^*, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru KakizakiNoritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Hironori Tanaka, Hiroki Nishikawa, Hiroshi Shibata, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada

^*この論文の責任著者

内科学（第三）講座

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.

本文言語	英語
論文番号	72
ジャーナル	Scientific Reports
巻	15
号	1
DOI	https://doi.org/10.1038/s41598-024-78539-4
出版ステータス	出版済み - 2025/12

ASJC Scopus 主題領域

一般

文献へのアクセス

10.1038/s41598-024-78539-4

フィンガープリント

「Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル

Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Ochi, H., Yasuda, S., Toyoda, H., Ogawa, C., Nishimura, T., Hatanaka, T., ... Kumada, T. (2025). Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib. Scientific Reports, 15(1), 記事 72. https://doi.org/10.1038/s41598-024-78539-4

@article{2da4d7abeb9241c7a3c1521690916821,

title = "Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib",

abstract = "In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.",

keywords = "CRP, GNRI, GNRI-C, Hepatocellular carcinoma, Lenvatinib",

author = "Hideko Ohama and Atsushi Hiraoka and Toshifumi Tada and Masashi Hirooka and Kazuya Kariyama and Joji Tani and Masanori Atsukawa and Koichi Takaguchi and Ei Itobayashi and Shinya Fukunishi and Kunihiko Tsuji and Toru Ishikawa and Kazuto Tajiri and Hironori Ochi and Satoshi Yasuda and Hidenori Toyoda and Chikara Ogawa and Takashi Nishimura and Takeshi Hatanaka and Satoru Kakizaki and Noritomo Shimada and Kazuhito Kawata and Atsushi Naganuma and Hisashi Kosaka and Tomomitsu Matono and Hidekatsu Kuroda and Yutaka Yata and Hironori Tanaka and Hiroki Nishikawa and Hiroshi Shibata and Fujimasa Tada and Kazuhiro Nouso and Asahiro Morishita and Akemi Tsutsui and Takuya Nagano and Norio Itokawa and Tomomi Okubo and Taeang Arai and Michitaka Imai and Yohei Koizumi and Shinichiro Nakamura and Hiroko Iijima and Masaki Kaibori and Yoichi Hiasa and Takashi Kumada",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2025",

month = dec,

doi = "10.1038/s41598-024-78539-4",

language = "英語",

volume = "15",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Ohama, H, Hiraoka, A, Tada, T, Hirooka, M, Kariyama, K, Tani, J, Atsukawa, M, Takaguchi, K, Itobayashi, E, Fukunishi, S, Tsuji, K, Ishikawa, T, Tajiri, K, Ochi, H, Yasuda, S, Toyoda, H, Ogawa, C, Nishimura, T, Hatanaka, T, Kakizaki, S, Shimada, N, Kawata, K, Naganuma, A, Kosaka, H, Matono, T, Kuroda, H, Yata, Y, Tanaka, H, Nishikawa, H, Shibata, H, Tada, F, Nouso, K, Morishita, A, Tsutsui, A, Nagano, T, Itokawa, N, Okubo, T, Arai, T, Imai, M, Koizumi, Y, Nakamura, S, Iijima, H, Kaibori, M, Hiasa, Y & Kumada, T 2025, 'Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib', Scientific Reports, vol. 15, no. 1, 72. https://doi.org/10.1038/s41598-024-78539-4

TY - JOUR

T1 - Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

AU - Ohama, Hideko

AU - Hiraoka, Atsushi

AU - Tada, Toshifumi

AU - Hirooka, Masashi

AU - Kariyama, Kazuya

AU - Tani, Joji

AU - Atsukawa, Masanori

AU - Takaguchi, Koichi

AU - Itobayashi, Ei

AU - Fukunishi, Shinya

AU - Tsuji, Kunihiko

AU - Ishikawa, Toru

AU - Tajiri, Kazuto

AU - Ochi, Hironori

AU - Yasuda, Satoshi

AU - Toyoda, Hidenori

AU - Ogawa, Chikara

AU - Nishimura, Takashi

AU - Hatanaka, Takeshi

AU - Kakizaki, Satoru

AU - Shimada, Noritomo

AU - Kawata, Kazuhito

AU - Naganuma, Atsushi

AU - Kosaka, Hisashi

AU - Matono, Tomomitsu

AU - Kuroda, Hidekatsu

AU - Yata, Yutaka

AU - Tanaka, Hironori

AU - Nishikawa, Hiroki

AU - Shibata, Hiroshi

AU - Tada, Fujimasa

AU - Nouso, Kazuhiro

AU - Morishita, Asahiro

AU - Tsutsui, Akemi

AU - Nagano, Takuya

AU - Itokawa, Norio

AU - Okubo, Tomomi

AU - Arai, Taeang

AU - Imai, Michitaka

AU - Koizumi, Yohei

AU - Nakamura, Shinichiro

AU - Iijima, Hiroko

AU - Kaibori, Masaki

AU - Hiasa, Yoichi

AU - Kumada, Takashi

PY - 2025/12

Y1 - 2025/12

N2 - In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.

AB - In the current era of immune therapy, lenvatinib (LEN) continues to be vital for treating unresectable hepatocellular carcinoma (uHCC) patients. This study investigates the importance of nutritional status in the prognosis of uHCC patients receiving LEN and evaluates a new prognostic scoring system that combines the geriatric nutritional risk index (GNRI) and systemic inflammatory response. From 2018 to 2022, 484 uHCC patients treated with LEN (384 males, median age 73). Prognostic value was compared between GNRI and C-reactive protein (CRP) scoring (GNRI-C score), GNRI, and neo-Glasgow prognostic score (neo-GPS). Evaluation was based on the Akaike information criterion (AIC) and concordance index(c-index). Median progression-free survival (mPFS) was 9.3/6.8/4.6 months for GNRI no-risk/low-risk/moderate-to-major risk (p < 0.01, AIC 4742.4/c-index 0.585). Median overall survival (mOS) was 27.8/15.2/9.5 months (p < 0.01, AIC 3433.34/c-index 0.639). For GNRI-C score, mPFS was 10.8/7.1/5.6/4.0 months (score 0/1/2/3) (p < 0.01, AIC 4732.82/c-index 0.6), while neo-GPS showed mPFS of 8.5/5.1/5.2 months (p < 0.01, AIC 4745.89/c-index 0.562). For mOS, GNRI-C score demonstrated 28.6/20.0/10.1/8.4 months (score 0/1/2/3) (p < 0.01, AIC 3420.27/c-index 0.652), while neo-GPS indicated 21.0/12.4/4.5 months (p < 0.01, AIC 3468.84/c-index 0.564). The newly devised GNRI-C score, incorporating nutritional and inflammatory markers, could offer improved prognostic predictions for uHCC patients treated with LEN.

KW - CRP

KW - GNRI

KW - GNRI-C

KW - Hepatocellular carcinoma

KW - Lenvatinib

UR - http://www.scopus.com/inward/record.url?scp=85214004488&partnerID=8YFLogxK

U2 - 10.1038/s41598-024-78539-4

DO - 10.1038/s41598-024-78539-4

M3 - 学術論文

C2 - 39747852

AN - SCOPUS:85214004488

SN - 2045-2322

VL - 15

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 72

ER -